China channel feed – Endpoints News

China channel feed

Lining up a filing for lead ROS1 inhibitor, transpacific oncology biotech AnHeart Therapeutics raises $61M

4 years ago

Qiming-backed CANbridge gets its Hong Kong IPO as Nasdaq slowdown prompts renewed market analysis

4 years ago

Vivo Capital, Bain, Primavera pour $200M into virtually unknown targeted oncology play out of China

4 years ago

Drugmakers cut prices on average by more than 60% to get on China's 2022 NDRL list — report

4 years ago

China boasts 48% price cut on insulin as domestic drugmakers eclipse Big Pharma in bulk order

4 years ago

After Big Pharma sparked interest in the US, Ablaze looks to bring radiopharmaceuticals overseas

4 years ago

China’s top mRNA contender is ready to go. And SoftBank just led a cash infusion pushing it over the $1B line

4 years ago

BeiGene gets the ball rolling on its 3rd IPO — and this one is expected to fetch $3B

4 years ago

Two of China's top PD-(L)1 players team up on CTLA-4 in $200M deal

4 years ago

CBC Group establishes new fund to meet China's booming life sciences real estate demand

4 years ago

China's Zai Lab spins 2 more licensing deals, including a sudden dive into neuroscience

4 years ago

A Bloomberg-backed cancer drug summit aims to thaw US-China relations

4 years ago

Perceptive steers LianBio's globally connected China strategy to $325M IPO

4 years ago

With Covid-19 vaccine in limbo, China's Fosun inks $628M deal for a Prevnar 13 rival

4 years ago

How China turned the tables on biopharma's global dealmaking

4 years ago

Bristol Myers wants to pull out of its Abraxane deal in China. BeiGene says no way

4 years ago

Unfazed by OS flop, Zai Lab eyes imminent China filing for MacroGenics' HER2 drug

4 years ago

Blacklist Chinese genetic sequencing companies, lawmakers argue — citing potential for 'bioweapons,' national security risk

4 years ago

I-Mab in talks about deals, stake sale to build on $3B AbbVie alliance — Bloomberg

4 years ago

Innovent bets $250M+ on Union's PDE4 inhibitor ahead of a PhII readout

4 years ago

Chinese biotech Everest signs $550M+ licensing deal for BTK inhibitors on heels of Covid-19 pact

4 years ago

Trans-Pacific power player Everest jumps on mRNA vaccine deal with Providence, paying $100M upfront to tap platform play

4 years ago

Sister to Juno's liso-cel, JW's relma-cel lands second-ever CAR-T approval in China

4 years ago

Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success

4 years ago

First page Previous page 11 12 131415 16 17 Next page Last page